<DOC>
	<DOCNO>NCT02512588</DOCNO>
	<brief_summary>This randomize , placebo-controlled , double-blind , multiple cohort , fixed-dose multiple crossover , dose-finding study oral BTD-001 adult patient IH Narcolepsy without cataplexy ( Type 2 ) .</brief_summary>
	<brief_title>A Study Safety Efficacy BTD-001 Treatment Patients With Idiopathic Hypersomnia ( IH ) Narcolepsy Type 2</brief_title>
	<detailed_description />
	<mesh_term>Narcolepsy</mesh_term>
	<mesh_term>Cataplexy</mesh_term>
	<mesh_term>Disorders Excessive Somnolence</mesh_term>
	<mesh_term>Hypersomnolence , Idiopathic</mesh_term>
	<criteria>Meets ICSD3 criterion IH Narcolepsy Type 2 undergo pharmacologic treatment condition Usual nightly total sleep least 6 hour single major rest period without nap Epworth Sleepiness Scale 10 great Males female age 18 65 year Any disorder cause hypersomnia IH Narcolepsy Type 2 Usual bedtime later midnight Seizure disorder history syncope , unexplained loss consciousness seizure past 3 year Beck Depression Inventory score great 19 Beck Anxiety Inventory score great 15 Significant history current suicidal ideation behavior BMI le 18 kg/m2 great 39 kg/m2 Positive toxicology screen breathalyzer test Clinically significant abnormal finding safety assessments Any significant medical psychiatric disease condition would put patient risk participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>